09/03/2021 (Agence Europe) – The Covid-19 vaccine marketed by Johnson & Johnson, which has yet to be authorised before being marketed in Europe, could be subject to delivery delays in the second quarter. This was revealed on Tuesday 9 March by the Reuters press agency after communication with a European official. By their account, J&J would face supply problems that would “put pressure” on its ability to meet its target of delivering 55 million doses by the end of June, saying the...